NDA 204977 · Osmotica Pharm US
Omtryg
Omega-3-Acid Ethyl Esters Type A · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Apr 23, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- OMTRYG · OMEGA-3-ACID ETHYL ESTERS TYPE A 1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Omega-3 Ethyl Esters Type A" as an intervention, any sponsor and status, largest first.
- ASCEND: A Study of Cardiovascular Events iN DiabetesPivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT00135226 · 15,480 participants · Start Mar 2005 · Primary completion Mar 12, 2018
Drug: Aspirin; Omega-3 Ethyl Esters and 2 more · For: Diabetes Mellitus
Sites: Oxford, United Kingdom
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00069784 · 12,537 participants · Start Aug 2003 · Primary completion Dec 2011
Drug: insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA) and 1 more · For: Diabetes Mellitus, Non-Insulin-Dependent
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 40 sites in all
AstraZenecaAstraZeneca (AZN)
NCT02370537 · 490 participants · Start Mar 2015 · Primary completion Nov 2015
Drug: Epanova® (omega-3 carboxylic acids); Omacor® (omega-3-acid ethyl esters) · For: Diabetes Mellitus, Type 2; Exocrine Pancreatic Insufficiency
Sites: Aarhus, Denmark; Frederiksberg, Denmark; København NV, Denmark · 22 sites in all
Eastern Virginia Medical SchoolAcademic, hospital or other
NCT00931879 · 44 participants · Start Oct 2009 · Primary completion Jul 2012
Drug: omega-3-ethyl esters; Placebo · For: Hypertriglyceridemia; Diabetic Neuropathy
Sites: Norfolk, Virginia
Thetis Pharmaceuticals LLCIndustry
NCT02113163 · 32 participants (planned) · Start Mar 2014 · Primary completion Jun 2014
Drug: Metformin Eicosapentaenoate; Metformin HCl and Vascepa · For: Diabetes Mellitus, Non-Insulin-Dependent; Hypertriglyceridemia
Sites: Baton Rouge, Louisiana
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Osmotica Pharm US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.